MELA Sciences to Host Investor Meeting in Conjunction With Melanoma Monday on May 6th 2013 in New York

MELA Sciences to Host Investor Meeting in Conjunction With Melanoma Monday on
May 6th 2013 in New York

IRVINGTON, N.Y., April 18, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed MelaFind^®, today
announced that it will be hosting a meeting for investors and analysts in
conjunction with Melanoma Monday on May 6, 2013 from 10:00am to 11:00am
Eastern time, in New York City.

Joseph V. Gulfo, MD, the Company's President and CEO, will host the meeting
and will provide a brief introduction and business update. He will then
moderate a panel discussion and presentations from leading dermatologists Mark
S. Nestor, MD, PhD, Voluntary Associate Professor of the Department of
Dermatology and Cutaneous Surgery at the University of Miami Miller School of
Medicine, and Dr. Gary Goldenberg, MD, Medical Director, Dermatology Faculty
Practice at The Mount Sinai Medical Center, Assistant Professor of Dermatology
and Pathology at the Mount Sinai School of Medicine. The clinicians will
discuss their current practice patterns, the clinical utility of MelaFind and
how they are incorporating it into their practice, as well as the product's
potential market opportunity. Following the presentations, there will be a
question and answer session.

A live audio webcast of the MELA Sciences Investor Meeting will be accessible
through the investor relations section of Company's website at
www.melasciences.com. An archived edition of the presentation will be
available later that day and will be available for at least 30 days afterward.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind^®, and its further design and development.
MelaFind is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind
has been approved by the U.S. Food and Drug Administration for use in the U.S.
In addition, MelaFind has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

CONTACT: For Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
        
         For Media
         Erica Sperling
         Rpr Marketing Communications
         212-317-1462
 
Press spacebar to pause and continue. Press esc to stop.